Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-12 8:41 pm Sale | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Versant Venture Capital VI, L.P. | 777,727 2.200% | -2,878,858 (-78.73%) | Filing History |
| 2021-02-11 4:54 pm Purchase | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Alkeon Capital Management LLC | 2,287,630 6.600% | 2,287,630 (New Position) | Filing History |
| 2021-02-11 3:50 pm Sale | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 3,493,419 10.100% | -13,809 (-0.39%) | Filing History |
| 2021-02-05 4:35 pm Sale | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | AMGEN INC AMGN | 1,508,375 4.344% | -397,323 (-20.85%) | Filing History |
| 2020-09-10 2:14 pm Purchase | 2020-08-31 | 13G | Akero Therapeutics, Inc. AKRO | JANUS HENDERSON GROUP PLC JHG | 3,507,228 10.100% | 1,097,695 (+45.56%) | Filing History |
| 2020-09-09 5:26 pm Sale | 2020-09-04 | 13D | Akero Therapeutics, Inc. AKRO | venBio Global Strategic Fund II L.P. | 2,668,717 7.700% | -653,421 (-19.67%) | Filing History |